Literature DB >> 24691059

Drug-disease interaction in elderly patients in family practice.

Peter Mand, Katharina Roth, Frank Biertz, Markus Kersting, Carsten Kruschinski, Guido Schmiemann, Eva Hummers-Pradier.   

Abstract

OBJECTIVE: To determine the frequency of potential drug-disease interaction in elderly patients in family practice. To assess which drugs and diagnoses are associated with a high risk related to drug-disease interaction and whether there are gender- or age-related differences.
METHODS: In routinely recorded electronic patient records, patients at least 65 years old with at least one diagnosis named in Beers list and one prescription were identified. Potential drug-disease interaction (PDDI) was presumed if within the same 3 months a "Beers" diagnosis and a potentially inappropriate prescription with respect to this diagnosis were documented for a patient. Multiple logistic regression analysis identified factors associated with a high risk of PDDI.
RESULTS: Of 24,619 patients (63.4% women) corresponding to our inclusion criteria, 10.4% were exposed to at least one PDDI. Almost no (0.0%) PDDI was associated with the most common Beers disorder hypertension (prevalence 49.2%). However, 23.4% of men suffering from bladder outflow obstruction (prevalence 17.6% in males) were exposed to at least one PDDI. PDDI was quite common in some rarer conditions, for example, indications for anticoagulation (prevalence 2.6%, 31.5% PDDI). PDDI was not influenced by gender, but associated with taking more than 4 drugs (OR 1.91 (1.83 - 2.00)), suffering from more than one Beers disorder (OR 1.24 (1.16 - 1.31)), and advanced age (OR 1.10 (1.05 - 1.15)).
CONCLUSIONS: High risk patient groups could be identified. Some disorders as well as some drugs are particularly prone to risky constellations; these should be reflected in systems assisting prescribing with regard to patient safety.

Entities:  

Mesh:

Year:  2014        PMID: 24691059     DOI: 10.5414/CP202003

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

Review 1.  Polypharmacy-an Upward Trend with Unpredictable Effects.

Authors:  Dirk Moßhammer; Hannah Haumann; Klaus Mörike; Stefanie Joos
Journal:  Dtsch Arztebl Int       Date:  2016-09-23       Impact factor: 5.594

Review 2.  Multimorbidity and Patient Safety Incidents in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Maria Panagioti; Jonathan Stokes; Aneez Esmail; Peter Coventry; Sudeh Cheraghi-Sohi; Rahul Alam; Peter Bower
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

3.  What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature.

Authors:  Ghadah Asaad Assiri; Nada Atef Shebl; Mansour Adam Mahmoud; Nouf Aloudah; Elizabeth Grant; Hisham Aljadhey; Aziz Sheikh
Journal:  BMJ Open       Date:  2018-05-05       Impact factor: 2.692

4.  Drug-disease interactions in Swedish senior primary care patients were dominated by non-steroid anti-inflammatory drugs and hypertension - a population-based registry study.

Authors:  Katharina Schmidt-Mende; Morten Andersen; Björn Wettermark; Jan Hasselström
Journal:  Scand J Prim Health Care       Date:  2020-07-29       Impact factor: 2.581

Review 5.  Factors associated with potentially inappropriate prescriptions and barriers to medicines optimisation among older adults in primary care settings: a systematic review.

Authors:  Zhijie Xu; Xujian Liang; Yue Zhu; Yiting Lu; Yuanqu Ye; Lizheng Fang; Yi Qian
Journal:  Fam Med Community Health       Date:  2021-11

6.  The effects of single and a combination of determinants of anaemia in the very old: results from the TULIPS consortium.

Authors:  Pin-Chun Wang; Jacobijn Gussekloo; Yasumichi Arai; Yukiko Abe; Jeanet W Blom; Rachel Duncan; Carol Jagger; Ngaire Kerse; Carmen Martin-Ruiz; Leah Palapar; Wendy P J den Elzen
Journal:  BMC Geriatr       Date:  2021-08-09       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.